Osilodrostat

Breastfeeding
  • TRADE NAME: Isturisa (Novartis)
  • INDICATIONS: Treatment of adult patients with Cushing’s disease
  • CLASS: Cortisol synthesis inhibitor
  • HALF-LIFE: ~ 4 hours

FDA APPROVAL DATE: 03/06/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Carbamazepine, Clarithromycin, CYP3A4 inhibitors, CYP3A4 inducers, CYP2B6 inducers, Itraconazole, Phenobarbital, Phenobarbital, Rifampin


No available data in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Osilodrostat blocks cortisol synthesis and may increase circulating levels of cortisol and aldosterone precursors (11-deoxy cortisol and 11-deoxycorticosterone) and androgens. Hypertension and hypokalemia were the most common adrenal hormone precursor-related adverse reactions observed in clinical trials.

Our database has 39 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 10/02/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top